61
Participants
Start Date
September 21, 2020
Primary Completion Date
October 2, 2024
Study Completion Date
July 31, 2039
NKX101 - CAR NK cell therapy
NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
Winship Cancer Institute, Emory University, Atlanta
Mayo Clinic Florida, Jacksonville
Sarah Cannon at TriStar Bone Marrow Transplant Center, Nashville
The Cleveland Clinic - Taussig Cancer Institute, Cleveland
University of Chicago Medical Center, Chicago
MD Anderson Cancer Center, University of Texas, Houston
Methodist Healthcare System of San Antonio, San Antonio
Colorado Blood Cancer Institute, Denver
Nkarta, Inc.
INDUSTRY